|
News
- January 16, 2007
 Samaritan
Pharmaceuticals Inc. (OTC BB:SPHC.OB), a developer of innovative
drugs, is pleased to announce that it has signed an exclusive
license with Molteni Farmaceutici, Italy in-licensing the
marketing and sales rights for six prescription medications:
Oramorph(tm), Morphine Sulphate, Methadone, Naloxone Molteni(tm),
Naltrexone(tm), and Mepivamol(tm), in Greece and Cyprus.
``Samaritan
commends Mr. Eugene Boyle and Dr. Christos Dakas for their
resiliency in exacting Samaritan's in-licensing revenue strategy.
Samaritan has advanced its first in-licensed drug Amphocil's
registration in Greece and expects sales revenue in 2007.
Samaritan believes its expertise in registration, marketing
and sales and distribution in overlooked territories such
as Eastern Europe will allow Samaritan to continually increase
its in-licensing portfolio of prescription drugs.'' said Dr.
Janet Greeson, CEO of Samaritan.
Samaritan
will distribute Molteni products through hospitals. Samaritan
plans to submit the products under this agreement to the Greece
and Cypress governmental market authorization authorities
for Greece and Cypress regulatory approval, as soon as Molteni
transfers the stated drugs' regulatory package.
http://www.samaritanpharma.com/marketed_products.asp
PAIN
RELIEF MEDICATIONS
About
Oramorph(tm)
Oramorph(tm)
is morphine sulphate in an oral solution and is used for managing
moderate to severe chronic pain.
About
Morphine Sulphate (Injectable Formulation)
Morphine
Sulphate relieves moderate to severe pain by binding to brain
receptors. Morphine Sulphate may be used to control the pain
following surgery, child birth, and other procedures. It may
also be used to treat the pain associated with cancer, heart
attacks, sickle cell disease and other medical conditions.
DRUG
ADDICTION THERAPY
About
Methadone
Methadone
is an opiate agonist. Methadone prevents heroin or morphine
from interacting with receptors for natural painkillers called
endorphins, blocking the effects of the addictive drugs and
reducing the physical cravings.
About
Naloxone Molteni(tm)
Naloxone
Molteni(tm) is an opioid antagonist which reverses the effects
of opioid overdose, for example heroin and morphine overdose.
Specifically, Naloxone(tm) is used in opioid overdoses for
countering life-threatening depression of the central nervous
system and respiratory system.
About
Naltrexone(tm)
Naltrexone(tm)
is an opioid antagonist which is used to help people who have
a narcotic or alcohol addiction stay drug free. Naltrexone(tm)
is used after the patient has stopped taking drugs or alcohol.
It works by blocking the effects of narcotics or by decreasing
the craving for alcohol.
ANESTHESIA
MEDICATION
About
Mepivamol(tm) (Mepivacaine)
Mepivamol(tm)
is an effective and reliable local anesthetic of intermediate
duration and low systemic toxicity. It is widely used for
regional anesthetic procedures such as IVRA, infiltration,
epidural blockade, plexus and peripheral nerve blockade.
About
Molteni Farmaceutici
Molteni
is rich in history with over a century of experience beginning
with the opening of its manufacturing facility at the Molteni
Pharmacy Laboratory located in the historic center of Florence,
Italy. The strategic therapeutic areas on which Molteni makes
an effort for trading new alliances are concentrated on Analgesia,
Anesthesia and Drug Addition Therapy.
About
Samaritan
Samaritan
is a small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
Samaritan
Pharmaceuticals: ``We LIV... to Save Lives.''
The company
disclaims any information that is created by an outside party
and endorses only information that is communicated by its
press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current
beliefs about the potential for its drug candidates, science
and technology. However, as with any biopharmaceutical under
development, there are significant risks and uncertainties
in the process of development and regulatory review. There
are no guarantees that products will prove to be commercially
successful. For additional information about the factors that
affect the company's business, please read the company's latest
Form 10-K/A filed November 2, 2006. The company undertakes
no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals,
Inc.
Kristi Eads
702-735-7001
###
|
